Mark F Maurer

1PUBLICATIONS
6CO-AUTHORS
Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (1)

|Apr 05, 2022
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.

Mark F Maurer, Katherine E Lewis, Joseph L Kuijper

Pageof 1

Frequent Collaborators

1 joint publications

Mark W Rixon

1 joint publications

Stacey R Dillon

1 joint publications

Yengo Raymond Kimbung

1 joint publications

Derek T Logan